Clinical trial
The MAX Study: Mitomycin C, Avastin and Xeloda in Patients With Untreated…
NCT00294359 · Australasian Gastro-Intestinal Trials Group, Other · Completed
Key facts
| NCT number | NCT00294359 |
|---|---|
| Title | The MAX Study: Mitomycin C, Avastin and Xeloda in Patients With Untreated Metastatic Colorectal Cancer |
| Official title | The MAX Study: A Randomised Phase II/III Study to Evaluate the Role of Mitomycin C, Avastin and Xeloda in Patients With Untreated Metastatic Colorectal Cancer |
| Lead sponsor | Australasian Gastro-Intestinal Trials Group, Other |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Metastatic Colorectal Cancer |
| Intervention type | Drug |
| Interventions | Mitomycin C, Capecitabine, Bevacizumab |
| Enrollment | 333 |
| Start date | Jun 1, 2005 |
| Completion | Jul 1, 2007 |
| First posted | Feb 22, 2006 |
| Last update posted | Aug 22, 2007 |
| Countries | Australia, New Zealand |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: